Radar satellite launched by India and NASA will track miniscule changes to Earth's land and ice
The $1.3 billion mission will help forecasters and first responders stay one step ahead of floods, landslides, volcanic eruptions and other disasters, according to scientists.
Rocketing to orbit from India, the satellite will survey virtually all of Earth's terrain multiple times. Its two radars — one from the U.S. and the other from India — will operate day and night, peering through clouds, rain and foliage to collect troves of data in extraordinary detail.
Microwave signals beamed down to Earth from the dual radars will bounce back up to the satellite's super-sized antenna reflector perched at the end of a boom like a beach umbrella. Scientists will compare the incoming and outgoing signals as the spacecraft passes over the same locations twice every 12 days, teasing out changes as small as a fraction of an inch (1 centimeter).
It's 'a first-of-its-kind, jewel radar satellite that will change the way we study our home planet and better predict a natural disaster before it strikes," NASA's science mission chief Nicky Fox said ahead of liftoff.
Fox led a small NASA delegation to India for the launch.
It will take a full week to extend the satellite's 30-foot (9-meter) boom and open the 39-foot-in-diameter (12-meter) drum-shaped reflector made of gold-plated wire mesh. Science operations should begin by the end of October.
Among the satellite's most pressing measurements: melting glaciers and polar ice sheets; shifting groundwater supplies; motion and stress of land surfaces prompting landslides and earthquakes; and forest and wetland disruptions boosting carbon dioxide and methane emissions.
NASA is contributing $1.2 billion to the three-year mission; it supplied the low-frequency radar and reflector. The Indian Space Research Organization's $91 million share includes the higher-frequency radar and main satellite structure, as well as the launch from a barrier island in the Bay of Bengal. It's the biggest space collaboration between the two countries.
The satellite called NISAR — short for NASA-ISRO Synthetic Aperture Radar — will operate from a near-polar-circling orbit 464 miles (747 kilometers) high. It will join dozens of Earth observation missions already in operation by the U.S. and India.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
8 minutes ago
- Medical News Today
Might a combination of 2 cancer drugs help treat Alzheimer's disease?
Researchers are actively seeking treatments or a cure for Alzheimer's diseaseOne current research avenue is to look at currently-approved medications that are used for other diseases, an approach that is called drug repurposing. A new study has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Researchers all over the world are actively seeking treatments or a cure for Alzheimer's disease — a form of dementia currently impacting about 32 million people globally. The medications used right now for Alzheimer's disease are designed to only help treat symptoms and slow disease progression. One avenue scientists are taking in an effort to find treatments for Alzheimer's disease is by looking at currently-approved medications that are used for other diseases, an approach called drug repurposing. 'The idea of drug repurposing or identifying new uses for existing drugs, can speed up the drug discovery process because the compounds already have been tested for toxicity and adverse events,' Marina Sirota, PhD, professor and interim director of the University of California — San Francisco Bakar Computational Health Sciences Institute explained to Medical News Today.'Alzheimer's disease is a complex disease, which is very difficult to treat so we need to use all the tools possible to speed up drug discovery and help patients,' said SirotaSirota is the co-senior author of a new study recently published in the journal Cellthat has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Focusing on cancer drugs letrozole and irinotecanFor this study, researchers began by using past studies to assess how Alzheimer's disease changed gene expression in brain cells, mainly neurons and glia. 'Glia cells are non-neuronal cells that provide support and protection to neurons in the nervous system,' Sirota explained. 'By targeting both neuronal cells and non-neuronal cells (glia) we hope to be able to more comprehensively target disease pathophysiology.' From there, scientists then took the gene expression signatures they found and used a database called the ConnectivityMap, allowing them to examine thousands of drugs to find ones that reversed the Alzheimer's disease gene expression signature.'We started with a set of 1,300 drugs and narrowed it down to the combination of letrozole and irinotecan through data driven analysis using both molecular and clinical data,' Sirota said.'We first identified compounds that reversed the cell type specific disease signatures back to normal based on the gene expression profiles. We then further filtered the list to the candidates that affect several cell types,' she explained.'Then we wanted to see whether patients who are on those drugs already have a lower risk of Alzheimer's disease by querying electronic medical records across the UC system,' she continued. 'This has allowed us to narrow our list down to a handful of drugs and focus on this combination.' The analysis of electronic medical records did indeed show that both drugs were associated with a significantly lower risk of Alzheimer's disease, confirming the of cancer drugs reverses brain cell damage, reduces protein build-up in mouse modelNext, researchers decided to test the combination of letrozole — used to treat breast cancer — and irinotecan — used to treat colorectal and lung cancer — in a mouse model of aggressive Alzheimer's disease. At the study's conclusion, Sirota and her team found that the drug combination overturned multiple aspects of Alzheimer's disease in the mouse model, including undoing the gene expression signature changes in the neurons and glia caused by the disease. Additionally, researchers found the combination cancer drugs helped reduce the amount of amyloid-beta and tau proteins in the brain, which are known hallmarks of Alzheimer's disease. 'This tells us that multiple levels of evidence — molecular data, clinical information and mouse model experiments are all aligning to tell us that these compounds might be helpful for Alzheimer's disease patients,' Sirota further noted that:'While we don't know the exact mechanism of how these drugs work to treat Alzheimer's disease, we know that irinotecan is a chemotherapy drug that works by inhibiting the enzyme DNA topoisomerase I, specifically targeting the S and G2 phases of the cell cycle. Letrozole's mechanism of action involves inhibiting the enzyme aromatase, which is crucial in the biosynthesis of estrogen.''However, we don't know whether it is the main aforementioned mechanisms or off-target effects of these drugs which might help Alzheimer's disease patients,' Sirota cautioned. 'Additional experiments need to be carried out to better understand how these two drugs might work together to combat Alzheimer's disease in patients.'Using 'big data' and inventive approaches to find potential Alzheimer's drug targetsMNT had the opportunity to speak with John Dickson, MD, PhD, a neurologist at Massachusetts General Hospital, about this research. 'This is an interesting and innovative paper that uses 'big data' to aid in identifying potential drug targets to treat Alzheimer's disease and then tests candidates in a preclinical model of Alzheimer's disease,' Dickson, who was not involved in this research, said.'Combining the use of transcriptomic data from brain tissue from Alzheimer's disease patients, drug perturbation studies in cell lines, and patient data from electronic medical records was an inventive approach to identifying and narrowing down potential drug targets,' he Dickson's view, 'the decision to use a dual-therapy approach and plan to target multiple cell types with this strategy was also innovative.''The combination of drugs showed beneficial effects on the memory testing and neuropathological findings in a mouse model of Alzheimer's disease. In addition to identifying two potential candidate therapies for Alzheimer's disease, this paper also provides an experimental paradigm for identifying new drugs to treat a variety of conditions,' he look at repurposing existing drugs for Alzheimer's treatment? MNT also talked to Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, about this study, who said it is refreshing to see data that supports improving memory loss through a novel mechanism that is not related to current therapies that work on brain acetylcholine, N-methyl-D-aspartate (NMDA), or amyloid.'This study's design is smart and the data is captivating,' Segil, who likewise was not involved in the research, added. 'Repurposing medications already being used has been extremely rewarding in neurologists and I truly hope something grows out of this research.' And Peter Gliebus, MD, neurologist and director of cognitive and behavioral neurology at Marcus Neuroscience Institute, part of Baptist Health South Florida, also not involved in the research, commented to MNT that this was a promising and exciting study, and said that repurposing existing drugs offers several advantages. 'Faster development since these drugs already have established safety profiles, which reduces the time and cost required for clinical trials,' Gliebus noted.'Cost-effectiveness [is achieved] by avoiding the high expenses associated with developing new drugs from scratch. And [this approach has] a broader impact, as many existing drugs may have unexplored mechanisms that could address complex Alzheimer's disease pathologies, such as neuroinflammation, synaptic dysfunction, and metabolic deficits.''Given the high failure rate of Alzheimer's drug trials, repurposing provides a practical and efficient pathway to identify effective treatments,' the neurologist concluded.
Daily Mail
9 hours ago
- Daily Mail
Andrew Garfield leaves fans confused by his 'freaky' face on new film set as he fuels plastic surgery rumors
Andrew Garfield has fans doing a double take after his latest appearance on the set of Artificial in San Francisco. The 41-year-old Spider-Man star looked noticeably different while filming the AI drama alongside Ike Barinholtz and Monica Barbaro. Garfield takes on the role of tech visionary Sam Altman, with Barinholtz as Elon Musk and Barbaro playing former OpenAI CTO Mira Murati. But it wasn't the star-studded cast or romance rumors with Barbaro that stirred chatter—it was Garfield's altered look that had fans buzzing. Many are now speculating if the actor underwent cosmetic procedures to achieve his new appearance. 'They did something real freaky to his face,' one critic wrote, as another added, 'Did he get bad botox?' But it wasn't the star-studded cast or romance rumors with costar Monica Barbaro that stirred chatter—it was Garfield's altered look that had fans buzzing Yet another chimed in, 'Did someone edit his face?' while another posted, 'I came to the comments to check if I was just crazy. What happened!?' 'Why does he look yassified,' one wrote. 'His whole eye area looks diff,' said another, while one fan admitted, 'I've never been so unattracted to Andrew Garfield before.' One summed it up: 'People are saying it's because he shaved but no. He looks very pale like he has makeup on? and then a facelift maybe? But that's insane if he did that.' The critic then made a robot reference, saying, 'It's giving uncanny valley and I feel bad judging but there is SOMETHING not right. We've all taken bad photos so I'm praying that's all it is' One simply said, 'He looks artificial.' Of course, some fans thought the actor looked incredible, with one writing, 'Andrew Garfield still looks 24 when he's actually 42 is an enigma to me.' The viral uproar comes after Garfield and Babar confirmed their romance as they joined the likes of Lily Collins and Poppy Delevingne at day seven of Wimbledon in July. The lovebirds, who reportedly seen smooching at Glastonbury the week before, put on a very cosy display while watching the centre court action, with the actor leaning in for a cheeky kiss. After sparking romance rumours in February, actor Andrew reportedly went public with his romance with the Top Gun: Maverick star Monica at Glastonbury. Speaking to The Sun , an onlooker at the festival said that Andrew and Monica are the 'real deal' and were seen holding hands, kissing and hugging. The pair are said to have stayed in the luxury teepee tents for the festival and spent their time moving between the VIP area and the main farm. 'On Friday she was posing for some pictures in the VIP area and he stood quite a distance away but looked really proud,' the source said. 'By Saturday they were holding hands and kissing and cuddling. They both seemed really happy and were singing along to Gracie Abrams during her set.
The Guardian
9 hours ago
- The Guardian
A professor had a $2.4m grant to study Black maternal health. Then Trump was elected
Jaime Slaughter-Acey was in a state of shock and anger when she learned that her National Institutes of Health (NIH)-funded study on birth outcomes in Black families was cancelled this spring. The University of North Carolina at Chapel Hill associate professor in epidemiology said that she felt like 'the rug was pulled out from under us' when the university called her to share the news. The termination notice said that the study no longer met the agency's priorities and didn't promise to increase life expectancy. 'It was heartbreaking,' Slaughter-Acey told the Guardian, 'and honestly, infuriating given the high rates of maternal and infant mortality in this country.' The cancellation came as the Trump administration terminated 1,902 NIH grants totalling more than $4.4bn between his January inauguration and the end of July, according to Grant Witness data. NIH followed guidance from the so-called 'department of government efficiency' (Doge) and Trump's executive orders to cut costs. Additionally, in April, the Trump administration let go of a majority of the staff at the federal Division of Reproductive Health, a Centers for Disease Control and Prevention (CDC) office that collects data on maternal experiences. It also surveils pregnancy-related deaths in an effort to reduce infant mortality and improve health outcomes for mothers and their children. Slaughter-Acey's several-year study funded by a more than $2.4m NIH grant aimed to look at how social and biological factors affect outcomes for more than 500 Black women in Detroit. The grant termination froze the team's more than $581,000 remaining funding. Through blood samples and surveys of Black mothers and grandmothers, Slaughter-Acey and her team aimed to understand if social environments accelerated how bodies physiologically age, otherwise known as biological ageing, which may lead to adverse pregnancy outcomes for Black women. She said that the research is 'designed to tell us how social environment and the pathways that social environment affects us physiologically, to then increase this risk that Black moms and Black babies have with respect to pregnancy'. While most studies that look at racism only focus on one point in time, Slaughter-Acey said that hers was 'the first study to comprehensively examine how exposure to structural, cultural and intergenerational racism throughout a Black woman's life impacts her epigenome and her child's birth outcomes.' It was also innovative because Black women are underrepresented in epigenomic studies, a field where researchers look at how environment and behavior impacts a person's genes, said Slaughter-Acey, due to medical mistrust and experiences of racism in the healthcare system. The NIH-grant cancellation in late March followed the release of data from the CDC revealing that Black women were the only race or ethnic group who didn't experience a decline in deaths from pregnancy related causes in 2023. Out of every 100,000 live births, 50.3 Black mothers died, compared with 14.5 deaths for white people, 12.4 for Latinos and 10.7 for Asians. The NIH didn't respond to a request for comment. Slaughter-Acey fears that the grant-cancellation signals that research and efforts to close the maternal death gap are at risk of coming to a standstill under the Trump administration. Other NIH grants that have been terminated include one that looked at prenatal exposure to public drinking water contaminants and a study that analyzed why women of color die of cervical cancer at a disproportionate rate. On Thursday, the Trump administration froze UCLA research grants from federal agencies including NIH and the National Science Foundation totaling nearly $200m, accusing the university of antisemitism and discrimination in admissions. 'It's part of a larger pattern of political interference in science that puts the health of all people at risk, especially vulnerable populations,' Slaughter-Acey said. The study 'is about understanding the root causes of poor maternal and infant health in this country – something that affects all of us, regardless of race or background. When science is silenced, communities suffer'. Still, Slaughter-Acey and her team are hopeful that the study will continue for years to come as they search for alternative funding sources, including donations. On Slaughter-Acey's LinkedIn page, she called upon her followers to donate to the University of North Carolina Department of Epidemiology, and to include a note that they support Slaughter-Acey's work, or the name of the study, 'LIFE-2'. 'The voices of these 500 plus moms and babies should not die or be silenced with the termination of this grant,' she told the Guardian. The pull in funding 'is an example of erasure of black mothers and infants'. There has been some temporary relief. This June, Slaughter-Acey's team received short-term funding from Michigan State University to continue their study over the next few months. Now nearly 600 moms are enrolled in the study, but without additional funding, it will probably pause again at the end of the year. The nearly 600 women who have joined the study were recruited from local delivery hospitals in Detroit, Michigan, in the day or two following childbirth. Slaughter-Acey chose Detroit since she completed her post-doc at the University of Michigan, where she researched the influence of social environments on Black maternal health. Participants for her study, which began in 2021, completed a post-delivery survey where they answered questions about social determinants of health including housing and food insecurity throughout their life. Along with collecting their blood through a finger prick, researchers also collect the babies' and mothers' birth certificates from the state health department as well as the mothers' blood that was collected at birth and stored in a biobank. About 20% of the babies' grandmothers are also participating in the study by answering questions about the social environment during their pregnancies and their daughters' early childhoods. The multilevel data collection allows the researchers to create 'this robust and triangulated dataset that includes social determinants of health, like information about food and housing insecurity', Slaughter-Acey said. 'It's capturing a more holistic view than what's been captured previously for moms in terms of maternal and infant health.' After the moms are discharged from the hospital, the researchers also follow up with a majority of the women eight to 10 weeks after they give birth to ask about their adjustment to motherhood, whether they've received support for breastfeeding, a postpartum healthcare visit, or if they've experienced discrimination from their healthcare providers. At the time of the funding termination, the research team was in the process of creating a 12-month postpartum checkup with the mothers to help define maternal thriving. 'When we are talking about maternal morbidity and mortality, we're defining maternal health by the absence of disease, by mom not dying, by mom not having a severe morbidity,' Slaughter-Acey said. 'But the field in general does not have a good understanding or even definition of, 'what does maternal thriving look like?' And we need to get past this conversation of maternal survival, and move to thriving.' More than two years of funding remained in the NIH grant, during which her team had planned to recruit more mothers and to conduct data analysis. They also aimed to create a website for participants to read about the study's findings. But the data that the team has analyzed thus far has revealed that mothers with a lot of adverse childhood experiences were more likely to have conflict with the father of the child. The finding, Slaughter-Acey said, 'underscores the importance of understanding how the social environment influences relationship dynamics and maybe perinatal outcomes. We know that social support is key during pregnancy'. The team also found that one in five study participants experienced housing insecurity during their pregnancy, a factor that she said greatly affects perinatal health and is rarely documented in hospital records. They also created a tool to measure racial microagressions from healthcare providers and in the mothers' everyday life, since many in the cohort said that they experienced harmful interactions that Slaughter-Acey said may explain why they felt unsupported. For Slaughter-Acey, the study findings 'highlight how structural inequities – across housing, healthcare, and personal history – intersect to shape maternal and infant outcomes. And they underscore why we need research that listens to and reflects the full complexity of Black women's experiences.' NIH research funding will probably continue to take a hit under the Trump administration. A new Trump administration policy requiring that multiyear grants be paid upfront lowers the odds that a research proposal will be accepted. As a result, university labs may close.
